EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections compared to Eylea. Read more here.

While orthopedic surgeons are paving the way for new procedures in 2025, old procedures that have been around for decades may be the key to cost effectiveness this year.